FCR (fludarabine, cyclophosphamide,
rituximab) has produced the
highest complete response (CR) rate
seen thus far in first-line treatment of
chronic lymphocytic leukemia (CLL),
according to investigator Michael J.
Keating, MD. The FCR regimen,
which is well tolerated, also results in
molecular remissions in a "significant
number" of complete responders, said
Dr. Keating, professor of medicine,
M.D. Anderson Cancer Center.